News Release

DolCas Biotech, LLC, has taken proactive actions in the form of a successful trademark-infringement suit to ensure its customers and consumers receive only the purest, truest turmeric. The forced legal action was taken to provide security to the consumer.

Three competitors, including contract manufacturers, agreed with Dolcas to all conditions settling the infringement of its U.S. trademark for BCM-95^® turmeric extract. The infringement on the BCM-95 brand had potential to impact consumer perception and hurt BCM-95’s leading position in the market, according to DolCas.

The committee found novelty in the patented turmeric extract ingredients, also taking into consideration the intellectual properties ingredient is backed by more than 30 clinical research studies conducted in leading universities and institutes worldwide. The committee concluded that DolCas is entitled to protection of its brands and trademarks.

“BCM-95 and Bio Curcumin® are registered trademarks of DolCas Biotech globally and we intend to protect them for the safety and security of consumers and of our brands," explained KG Rao, CEO of DolCas. “The three companies have now promised not to use our trademarks in the market and have completed the payments for the infringement. The payments will, in part, be applied to continued research into the multiple health benefits and efficacy of our line of pure turmeric extracts."

The company estimates that BCM-95 turmeric extract has a market share of 30 percent in the United States, and it has an exclusive contract with EuroPharma to market BCM-95 at health food stores in the United States/Canada.

For more information, visit dolcas-biotech.com, or visit DolCas Biotech at booth MM176 at SupplySide West.

Interested in attending SupplySide West? Visit supplysideshow.com to for more information and to register to attend.